Iterum Therapeutics plc (ITRM) Stock Analysis

Iterum Therapeutics plc (ITRM) Healthcare & Pipeline Overview

Iterum Therapeutics plc is a clinical-stage pharmaceutical company specializing in anti-infectives, with its lead product, sulopenem, undergoing Phase III clinical trials. Targeting unmet needs in urinary tract and intra-abdominal infections, Iterum operates in a competitive biotechnology landscape, striving for regulatory approvals and market access.

What Is the Investment Thesis for ITRM?

Iterum Therapeutics presents a high-risk, high-reward investment opportunity centered on the potential success of sulopenem. The company's focus on addressing antibiotic resistance in uUTI, cUTI, and cIAI aligns with a critical healthcare need. Successful completion of Phase III trials and subsequent regulatory approval for sulopenem could drive significant value. However, the company's negative profit margin of -6913.1% and gross margin of -171.3% highlight its current financial challenges. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure funding to support ongoing operations and commercialization efforts. The high beta of 3.01 indicates significant volatility, making this investment suitable for risk-tolerant investors.

Based on FMP financials and quantitative analysis

ITRM Key Highlights

Sulopenem is in Phase III clinical trials targeting uncomplicated and complicated urinary tract infections, and complicated intra-abdominal infections.

• The company's focus on anti-infectives addresses the growing global problem of antibiotic resistance.
• Iterum Therapeutics operates in Ireland, Bermuda, and the United States.
• The company has a negative profit margin of -6913.1% and a negative gross margin of -171.3%.
• The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Who Are ITRM's Competitors?

ITRM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ITRM's Key Strengths?

Novel anti-infective compound (sulopenem).

• Phase III clinical trials underway.
• Addresses unmet medical needs in antibiotic resistance.
• Oral and IV formulations offer flexibility.

What Are ITRM's Weaknesses?

Clinical-stage company with no approved products.

• Negative profit and gross margins.
• Reliance on successful development and approval of sulopenem.
• Limited financial resources.

What Could Drive ITRM Stock Higher?

Announcement of Phase III clinical trial results for sulopenem in uUTI.

• Regulatory submission to the FDA for sulopenem approval.
• Potential partnership or licensing agreement for sulopenem commercialization.
• Enrollment and completion of ongoing clinical trials.

What Are the Key Risks for ITRM?

Financial-distress signal — its Altman Z-Score of -23.98 sits in the distress zone (elevated bankruptcy risk).

• Failure to achieve positive results in Phase III clinical trials.
• Regulatory rejection or delays in approval of sulopenem.
• Competition from established pharmaceutical companies with existing anti-infective products.
• Dependence on securing additional funding to support operations.
• Generic entry after patent expiration.

What Are the Growth Opportunities for ITRM?

• Successful Completion and Approval of Sulopenem: The primary growth driver for Iterum is the successful completion of Phase III clinical trials and subsequent regulatory approval of sulopenem for uUTI, cUTI, and cIAI. Achieving FDA approval in the US and EMA approval in Europe would open access to a multi-billion dollar market, addressing a critical unmet need for effective treatments against resistant bacteria. Timeline: Anticipated regulatory submissions within the next 12-18 months, with potential approval by late 2027.
• Expansion into Additional Indications: Iterum can explore expanding the use of sulopenem into additional indications beyond uUTI, cUTI, and cIAI. This could include targeting other types of bacterial infections or developing sulopenem for use in specific patient populations, such as those with compromised immune systems. Expanding the label for sulopenem would significantly increase its market potential. Timeline: Exploration of new indications could begin within 2-3 years following initial regulatory approvals.
• Strategic Partnerships and Licensing Agreements: Iterum can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to support the commercialization of sulopenem. Partnering with a company with established sales and marketing infrastructure would accelerate market penetration and maximize revenue potential. Licensing agreements could also generate upfront payments and royalties. Timeline: Active pursuit of partnerships and licensing agreements concurrent with regulatory approval processes.
• Development of Novel Anti-Infectives: Iterum can leverage its expertise in anti-infective drug development to develop additional novel therapies targeting other types of bacterial infections. Building a pipeline of anti-infective candidates would diversify the company's product portfolio and reduce its reliance on sulopenem. This would also enhance its long-term growth prospects. Timeline: Initiation of early-stage development programs within the next 3-5 years.
• Geographic Expansion: Beyond the US and Europe, Iterum can expand its geographic reach to other markets, such as Asia and Latin America, where there is a growing need for effective anti-infective therapies. Entering new markets would require navigating local regulatory requirements and establishing distribution networks. However, it would significantly increase the company's addressable market. Timeline: Exploration of geographic expansion opportunities within 3-5 years following initial commercial launch.

What Are ITRM's Competitive Advantages?

• Patent protection for sulopenem.
• Clinical trial data demonstrating efficacy against resistant bacteria.
• Expertise in anti-infective drug development.
• First-mover advantage in addressing unmet needs in specific infection types.

What Does ITRM Do?

Iterum Therapeutics plc, incorporated in 2015 and headquartered in Dublin, Ireland, is a clinical-stage pharmaceutical company dedicated to developing and commercializing innovative anti-infectives. The company focuses on addressing the growing global problem of antibiotic resistance by developing new and effective therapies for multi-drug resistant organisms. Its lead product candidate, sulopenem, is a novel anti-infective compound with both oral and IV formulations. Sulopenem is currently in Phase III clinical trials for the treatment of uncomplicated urinary tract infections (uUTI), complicated urinary tract infections (cUTI), and complicated intra-abdominal infections (cIAI). These infections represent significant unmet medical needs, particularly in the face of increasing antibiotic resistance. Iterum's strategic focus is on advancing sulopenem through the regulatory approval process and preparing for its commercial launch, aiming to provide a much-needed treatment option for patients and healthcare providers. The company operates in Ireland, Bermuda, and the United States, reflecting its global ambitions and market reach.

What Products and Services Does ITRM Offer?

• Develops and commercializes anti-infective drugs.
• Focuses on combating multi-drug resistant organisms.
• Conducts Phase III clinical trials for sulopenem.
• Targets uncomplicated and complicated urinary tract infections.
• Targets complicated intra-abdominal infections.
• Offers both oral and IV formulations of sulopenem.
• Aims to address unmet medical needs in infectious diseases.

How Does ITRM Make Money?

• Develops novel anti-infective compounds.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from FDA and EMA.
• Commercializes approved drugs through sales and marketing efforts.

What Industry Does ITRM Operate In?

Iterum Therapeutics operates within the biotechnology sector, specifically focusing on anti-infectives. The market for anti-infective drugs is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for new treatment options. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel antibiotics. Iterum's success depends on its ability to navigate the complex regulatory environment, secure funding, and effectively commercialize its lead product, sulopenem. The global anti-infectives market is projected to grow, driven by the ongoing need to combat infectious diseases.

Who Are ITRM's Key Customers?

• Hospitals and healthcare providers treating patients with bacterial infections.
• Patients suffering from urinary tract infections and intra-abdominal infections.
• Pharmacies dispensing anti-infective medications.
• Government healthcare systems.

Wall Street analysts project Iterum Therapeutics plc revenue of about $9.4M for fiscal 2026, with EPS near $-0.31.

Iterum Therapeutics plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -23.98 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Iterum Therapeutics plc stands at 442.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.7%, showing how much profit it generates from its asset base. A current ratio of 2.13 indicates the company holds enough short-term assets to cover its near-term obligations.

Iterum Therapeutics plc (ITRM) Valuation Context

Valued at $1.60M, ITRM is classified as a micro-cap stock.

Company Profile

Iterum Therapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Corey N. Fishman. ITRM has traded publicly since 2018.

ITRM Financials

ITRM Latest News

Common Questions About ITRM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources